RxDoctor Payments DataLook up a doctor →

Megan Johnson

Physician Assistant · Shreveport, LANPI 1902051386

Payments from drug & device makers

$11,778in general payments, 2019–2025

Across 650 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Evoke Pharma, Inc.$527
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$11,42197%
  • Education$3563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,778 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$61,995
Medicare patients
382
Services billed
636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab31$835,334
Skyrizi On-BodyRisankizumab-Rzaa15$313,047
CreonLipase/Protease/Amylase47$190,321
ZenpepLipase/Protease/Amylase23$125,847
LinzessLinaclotide61$47,961
TrulancePlecanatide56$33,456
MotegrityPrucalopride Succinate32$16,548
Pantoprazole Sodium711$10,213
Sucralfate122$7,877
Rabeprazole Sodium240$7,670
NexiumEsomeprazole Magnesium13$6,558
Esomeprazole Magnesium154$5,669
Lubiprostone45$5,544
Mesalamine23$5,061
Omeprazole433$5,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,732$835,33431 claims
AbbVieCreon, Linzess$2,900$238,282108 claims
Aimmune Therapeutics, Inc.Zenpep$83$125,84723 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,263$33,45656 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,004$16,54832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →